- Home
- ADC vs BMRN Comparison
ADC vs BMRN Comparison
Compare ADC & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADC | BMRN |
|---|---|---|
| Founded | 1971 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 11.4B |
| IPO Year | 1996 | 1999 |
Fundamental Metrics
Financial Performance| Metric | ADC | BMRN |
|---|---|---|
| Price | $74.45 | $67.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 18 |
| Target Price | $84.50 | ★ $88.22 |
| AVG Volume (30 Days) | 1.2M | ★ 2.3M |
| Earning Date | 04-21-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.94 | 0.77 |
| Revenue | $718,398,000.00 | ★ $1,313,646,000.00 |
| Revenue This Year | $12.01 | $15.02 |
| Revenue Next Year | $9.90 | $12.23 |
| P/E Ratio | ★ $79.14 | $90.04 |
| Revenue Growth | 16.42 | ★ 17.62 |
| 52 Week Low | $69.56 | $49.26 |
| 52 Week High | $82.08 | $70.98 |
Technical Indicators
Market Signals| Indicator | ADC | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 38.66 | 62.79 |
| Support Level | $73.45 | $51.59 |
| Resistance Level | $76.38 | $70.98 |
| Average True Range (ATR) | 1.12 | 2.11 |
| MACD | -0.23 | 0.24 |
| Stochastic Oscillator | 23.08 | 73.82 |
Price Performance
Historical ComparisonAbout ADC Agree Realty Corporation
Agree Realty Corporation operates as a fully integrated real estate investment trust mainly focused on the ownership, acquisition, development and management of retail properties net leased to industry-tenants. The Company is mainly in the business of acquiring, developing and managing retail real estate. Some of its properties in the portfolio include Walmart, 7-Eleven, Wawa, Gerber Collision and others.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.